The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > ORGANIZATION
ORGANIZATION
- US Tariffs Would Hinder Access to Innovative Drugs: JPMA President
April 24, 2025
- JPMA to Discuss Ways to Promote DX in Commercial Production in FY2025
April 23, 2025
- New JPMA Task Force to Respond to ICH-GL and PMD Act Amendments
April 22, 2025
- JPMA to Investigate the Status of Application of Japanese PI Waiver
April 22, 2025
- PhRMA HTA Taskforce Warns CEA Expansion Will Accelerate Drug Loss in Japan
April 18, 2025
- JPMA Sets Up Response Team to Collect Info on US Tariff Measures
April 18, 2025
- Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
April 17, 2025
- JGA to Release Interim Report on Industry Revamp in June: President
April 14, 2025
- Contradictions in Drug Pricing System Can No Longer Be Overlooked: Ex-Bureaucrat
April 10, 2025
- Pivot Away from Social Security Spending Cap: Labor Union to Govt
April 10, 2025
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
- Japan Generic Use Rate Vaults to 88.6% in October-December: JGA
April 7, 2025
- JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
April 2, 2025
- Iwaya Reappointed as EFPIA Japan Chair for 2-Year Term
April 1, 2025
- Payer Kyokai Kenpo Ups Target for Biosimilar Use
March 25, 2025
- FPMAJ Maps Out Planned Activities for FY2025
March 24, 2025
- JEMA Proposing “Improved Drug” Category with Minimal Application Dossiers
March 10, 2025
- Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
- JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
- People’s Trust in Pharma Industry Down to 83.9% in 2024: JPMA Poll
February 27, 2025
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…